drugset / Trial / NCT00107393

Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer

NCT00107393 ↗

Phase 2 Completed 75 enrolled Tohoku University
Open-labelTreatment

Summary

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving trastuzumab together with capecitabine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving trastuzumab together with capecitabine works in treating women with metastatic breast cancer.

Timeline

Start
2003-06
Primary completion
2008-05
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1657 mg/m2 Oral
Subject Trastuzumab Monoclonal antibody 2 mg/kg Intravenous

Indications